STOCK TITAN

DWPT Stock News

DWPT NASDAQ
Rhea-AI Summary

Dewpoint Therapeutics (DWPT) and Cancer Research UK signed a collaboration and licence agreement to advance DPTX8743 into clinical development.

Cancer Research UK’s Centre for Drug Development will fund, sponsor and execute studies needed for a Clinical Trial Application and a first-in-human Phase 1/2a trial. The collaboration aims to evaluate safety and establish clinical proof of concept in MYC-driven cancers. DPTX8743 targets molecular clusters called condensates involved in MYC-dependent gene activity; in preclinical models, it disrupted these clusters, suppressed MYC-driven gene expression and induced tumour cell death.

Dewpoint retains all rights to DPTX8743 and may license results and intellectual property arising from the collaboration. Cancer Research UK is eligible for downstream milestone payments and royalties. Cancer Research Horizons will manage the commercial relationship.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership clinical trial